Phase I (2000-05)

in page functions

In the 2000-05 period, Gavi focused on getting funds to countries quickly to extend the reach and quality of immunisation programmes.

In Gavi's first five years, the Vaccine Alliance concentrated on two primary areas:

  1. supply of new and underused vaccines;
  2. strengthening vaccine delivery systems.

From 2000-05, Gavi's new and underused vaccine support (NVS) focused on three underused vaccines: hepatitis B (hepB), Haemophilus influenzae type b (Hib) and yellow fever.

Support was provided in the form of five-year grants with the expectation that countries would increase their national contribution, leading to eventual financial sustainability.

Delivery systems were improved through Gavi's injection safety support (INS) initiatives. As most infections result from the re-use of equipment, Gavi enabled the supply of disposable auto-disable (AD) syringes for all vaccines to all countries. In addition to minimising infection risk, this helped to drive down the price of AD syringes and increased vaccine demand.

Incentives to immunise more children were given through performance-based funding known as immunisation services support (ISS) with countries receiving extra money per additional child immunised.

US$ 1 = US$ 18

A study in Health Affairs covering 73 Gavi-supported countries over the 2011–2020 period shows that, for every US$ 1 spent on immunisation, US$ 18 are saved in healthcare costs, lost wages and lost productivity due to illness. If we take into account the broader benefits of people living longer, healthier lives, the return on investment rises to US$ 48 per US$ 1 spent.

Ozawa S, Clark S, Portnoy A et al. Return on investment from childhood immunizations in low- and middle-income countries, 2011-20, Health Affairs 2016

More facts...

close icon

modal window here